Prelude Therapeutics vs Tango Therapeutics
PRLD and TNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PRLD and TNGX compare
Tango Therapeutics is the larger company, worth 14 times as much as Prelude Therapeutics ($4.3B against $302M).
Prelude Therapeutics grew revenue faster over the last twelve months (220% versus −100% for Tango Therapeutics).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PRLD | TNGX |
|---|---|---|
| Size and price | ||
| Market cap | $302M | $4.3B |
| Share price | $3.78 | $25.73 |
| Change, 1 year | 200% | 224% |
| Change, 5 years | −73.9% | 115% |
| Beta (5Y) | 1.24 | 1.18 |
| Employees | 79 | 137 |
| StockData Score | ||
| Total score | 8 | 8 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 | 1 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 13.5× | – |
| P/B | 2.3× (better) | 4.4× |
| FCF yield | −11.0% | −3.5% (better) |
| Fair value | $2.16 | – |
| Margin of safety | −74.8% | – |
| Growth | ||
| Revenue growth (TTM) | 220% (better) | −100% |
| Revenue growth, 5Y average | – | 52.1% |
| Profitability | ||
| Operating margin | −301% | – |
| Net margin | −270% | – |
| FCF margin | −148% | – |
| Return on equity | −57.7% | −36.5% (better) |
| Return on invested capital | – | −3646% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 4.07 | 39.45 (better) |
| Altman Z-score | −2.29 | 48.20 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 62.2% | 127% |
| Held by insiders | 40.5% | 11.7% |
| Insider net buying, 12 months | $25.0M (better) | −$8.0M |
| Short interest, % of float | 8.8% | 32.4% |
Go deeper
- PRLD stock overview
- PRLD income statement
- PRLD valuation and score
- TNGX stock overview
- TNGX income statement
- TNGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.